Early treatment window for predicting breast cancer response to neoadjuvant chemotherapy in the HR+/HER2-subgroup using diffuse optical tomography

被引：0
|
作者：
Altoe, Mirella L. [1 ]
Marone, Alessandro [1 ]
Kim, Hyun K. [1 ,2 ]
Guo, Hua [3 ]
Hibshoosh, Haninna [3 ]
Tejada, Mariella [4 ]
Crew, Katherine D. [4 ,5 ]
Accordino, Melissa K. [4 ]
Trivedi, Meghna S. [4 ]
Kalinsky, Kevin [4 ]
Hershman, Dawn L. [4 ,5 ]
Hielscher, Andreas H. [1 ]
机构：
[1] NYU, Tandon Sch Engn, Dept Biomed Engn, Brooklyn, NY 11201 USA
[2] Columbia Univ, Dept Radiol, Irving Med Ctr, New York, NY 10032 USA
[3] Columbia Univ, Dept Pathol & Cell Biol, Irving Med Ctr, New York, NY 10032 USA
[4] Columbia Univ, Dept Med, Irving Med Ctr, Div Hematol Oncol, New York, NY 10032 USA
[5] Columbia Univ, Dept Epidemiol, Irving Med Ctr, New York, NY 10032 USA
来源：
MULTISCALE IMAGING AND SPECTROSCOPY III | 2022年 / 11944卷
关键词：
Difuse optical tomography; deoxy-hemoglobin; breast cancer; neoadjuvant chemotherapy; pCR; molecular subtype; HR+/HER2-;
D O I：
10.1117/12.2609729
中图分类号：
R318 [生物医学工程];
学科分类号：
0831 ;
摘要：
This work evaluates changes in features of 3D breast images generated by a so-called dynamic optical tomographic imaging system (DOTBIS)during neoadjuvant chemotherapy (NAC). Images from 23 breast cancer patients were analyzes and correlated with respect to treatment outcome and status of hormone receptors and human epidermal growth factor receptors. Our data shows that the ratio of the mean value of deoxy-hemoglobin (ctHHbN) at two weeks after the first treatment compared to baseline was statistically significantly lower in patients that achieve a pathologic complete response (pCR) (0.77 +/- 0.22) as compared to patients with a non-pCR (1.14 +/- 0.24, P <.005). These observations indicate that early changes in DOTBIS images can potentially be used to predict breast cancer response to NAC and may allow a better way to customize therapy to HR+/HER2- patients in order to optimize treatment.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer
    Yu, Ying-hua
    Zhu, Xiao
    Mo, Qin-guo
    Cui, Ying
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (04): : 524 - 533
  • [22] Controversies on chemotherapy for early HR+/HER2-breast cancer: the role of anthracyclines and dose intensification
    Poggio, Francesca
    Molinelli, Chiara
    Giannubilo, Irene
    Lambertini, Matteo
    Blondeaux, Eva
    CURRENT OPINION IN ONCOLOGY, 2024, 36 (06) : 495 - 502
  • [23] Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2-breast cancer
    Martinez-Perez, Carlos
    Turnbull, Arran K.
    Kay, Charlene
    Dixon, J. Michael
    EXPERT REVIEW OF ANTICANCER THERAPY, 2023, 23 (01) : 67 - 86
  • [24] Current trends in the treatment of HR+/HER2+breast cancer
    Kay, Charlene
    Martinez-Perez, Carlos
    Meehan, James
    Gray, Mark
    Webber, Victoria
    Dixon, J. Michael
    Turnbull, Arran K.
    FUTURE ONCOLOGY, 2021, 17 (13) : 1665 - 1681
  • [25] Predicting Tumor Response in Breast Cancer Patients Using Diffuse Optical Tomography
    Gunther, Jacqueline E.
    Lim, Emerson
    Kim, Hyun Keol
    Flexman, Molly
    Refice, Susan
    Brown, Mindy
    Kalinsky, Kevin
    Hershman, Dawn
    Hielscher, Andreas H.
    DIFFUSE OPTICAL IMAGING IV, 2013, 8799
  • [26] The optimal neoadjuvant treatment regimen for HR+/HER2+breast cancer: a network meta-analysis
    Wang, Hao
    Liu, Shiwei
    Yu, Miao
    Mi, Kun
    Mou, Exian
    Xia, Li
    Xie, Weimin
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    CANCER RESEARCH, 2024, 84 (09)
  • [27] Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2-Breast Cancer: Impact of Tumor Ki67 and ER Status
    Akdag, Goncagul
    Yildirim, Sedat
    Dogan, Akif
    Yasar, Zeynep Yuksel
    Bal, Hamit
    Kinikoglu, Oguzcan
    Oksuz, Sila
    Ozkerim, Ugur
    Tunbekici, Salih
    Yildiz, Hacer Sahika
    Turkoglu, Ezgi
    Alan, Ozkan
    Kokten, Sermin Coban
    Isik, Deniz
    Sever, Ozlem Nuray
    Odabas, Hatice
    Yildirim, Mahmut Emre
    Turan, Nedim
    CHEMOTHERAPY, 2024, 69 (03) : 141 - 149
  • [28] The optimal neoadjuvant treatment strategy for HR+/HER2+breast cancer: a network meta-analysis
    Liu, Shiwei
    Yu, Miao
    Mou, Exian
    Wang, Meihua
    Liu, Shuanghua
    Xia, Li
    Li, Hui
    Tang, Hao
    Feng, Yajing
    Yu, Xin
    Mi, Kun
    Wang, Hao
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [29] Diffuse optical tomography can predict pathologic complete response in patients with HER2+or triple negative breast cancer undergoing neoadjuvant chemotherapy
    Kalinsky, K.
    Lee, S.
    Zhong, X.
    Lim, E. A.
    Gunther, J. E.
    Hibshoosh, H.
    Kim, H. K.
    Accordino, M.
    Crew, K.
    Hielscher, A.
    Hershman, D. L.
    CANCER RESEARCH, 2017, 77
  • [30] ACRIN 6691 monitoring and predicting breast cancer neoadjuvant chemotherapy response using diffuse optical spectroscopic imaging (DOSI)
    Tromberg, B. J.
    Butler, J. A.
    Mankoff, D. A.
    Isakoff, S. J.
    Hylton, N. M.
    Yodh, A. G.
    Boas, D.
    Paulsen, K.
    Pogue, B. W.
    Kaufman, P. A.
    Mehta, R. S.
    Carpenter, P. M.
    Cerussi, A.
    Zhang, Z.
    Hartfeil, D. M.
    L'Heureux, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345